%0 Journal Article
%T Automated Indirect Immunofluorescence Evaluation of Antinuclear Autoantibodies on HEp-2 Cells
%A J£¿rn Voigt
%A Christopher Krause
%A Edda Rohw£¿der
%A Sandra Saschenbrecker
%A Melanie Hahn
%A Maick Danckwardt
%A Christian Feirer
%A Konstantin Ens
%A Kai Fechner
%A Erhardt Barth
%A Thomas Martinetz
%A Winfried St£¿cker
%J Journal of Immunology Research
%D 2012
%R 10.1155/2012/651058
%X Indirect immunofluorescence (IIF) on human epithelial (HEp-2) cells is considered as the gold standard screening method for the detection of antinuclear autoantibodies (ANA). However, in terms of automation and standardization, it has not been able to keep pace with most other analytical techniques used in diagnostic laboratories. Although there are already some automation solutions for IIF incubation in the market, the automation of result evaluation is still in its infancy. Therefore, the EUROPattern Suite has been developed as a comprehensive automated processing and interpretation system for standardized and efficient ANA detection by HEp-2 cell-based IIF. In this study, the automated pattern recognition was compared to conventional visual interpretation in a total of 351 sera. In the discrimination of positive from negative samples, concordant results between visual and automated evaluation were obtained for 349 sera (99.4%, kappa = 0.984). The system missed out none of the 272 antibody-positive samples and identified 77 out of 79 visually negative samples (analytical sensitivity/specificity: 100%/97.5%). Moreover, 94.0% of all main antibody patterns were recognized correctly by the software. Owing to its performance characteristics, EUROPattern enables fast, objective, and economic IIF ANA analysis and has the potential to reduce intra- and interlaboratory variability. 1. Introduction The detection of autoantibodies against the cell nuclei (ANA) and cytoplasmic components plays an important role in the diagnosis of many autoimmune diseases, such as systemic lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis, progressive systemic sclerosis, dermato-/polymyositis, Sj£¿gren¡¯s syndrome, and chronic active autoimmune hepatitis. The prevalence of ANA varies between 20 and 100%, depending on the disease and type of antibody [1¨C4]. The gold standard for ANA screening is indirect immunofluorescence (IIF) on human epithelial (HEp-2) cells [5¨C7]. Displaying a multitude of authentic autoantigens, this antigenic substrate enables highly sensitive preidentification of autoantibodies by their characteristic fluorescence patterns [8], and the determination of their titers. In addition, the confirmation of positive screening results and the identification of single ANA specificities by monospecific immunoassays (e.g., enzyme-linked immunosorbent assay (ELISA) or immunoblot) are recommended to support differential diagnosis, disease monitoring, and prognostic assessment. This two-step strategy has been challenged by automated ELISA and
%U http://www.hindawi.com/journals/jir/2012/651058/